


AMENDMENTS TO THE CLAIMS

1. **(Currently Amended)** A method of Use of a compound of formula I', in the manufacture of a medicament for the treatment or prophylaxis of plasmodium infections in mammals, including man, comprising administering to an individual in need thereof an effective amount of formula I:-



where

A is O, S or CH₂;

B is O, S or CHR³;

R¹ is H, C₁-C₅ alkyl, C₂-C₅ alkenyl, C₂-C₅ alkynyl or a 5 or 6 membered, saturated or unsaturated ring containing 0 to 3 heteroatoms selected from N, O and S, the alkyl, alkenyl, alkynyl or ring being independently optionally substituted with R⁴;

R² is H, F;

R³ is H, F, OH, NH₂ or a pharmaceutically acceptable ester, amide or ether thereof; or

R² and R³ together form a chemical bond;

D is -NHCO-, -CONH-, -O-, -C(=O)-, -CH=CH-, -C≡C-, -NR⁵-;

R⁴ is independently selected from hydrogen, halo, cyano, amino, nitro, carboxy, carbamoyl, hydroxy, oxo, C₁-C₅ alkyl, C₁-C₅ haloalkyl, C₁-C₅ alkyloxy, C₁-C₅ alkanoyl, C₁-C₅ alkanoyloxy, C₁-C₅ alkylthio, -N(C₀-C₃-alkyl)₂, hydroxymethyl, aminomethyl, carboxymethyl; -SO_nN(C₀-C₃-alkyl), -SO_nC₁-C₅-alkyl, where n is 1 or 2;

R⁵ is H, C₁-C₄ alkyl, C₁-C₄ alkanoyl;

E is Si or C;

R⁶, R⁷ and R⁸ are independently selected from C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, or a stable monocyclic, bicyclic or tricyclic ring system which is saturated or unsaturated in which each ring has 0 to 3 heteroatoms selected from N, O and S;

R⁶, R⁷ and R⁸ are independently optionally substituted with R⁴;

with the proviso that if R³ is H, OH, F, NH₂ or a bond, then at least one of R⁶, R⁷ and/or R⁸ comprises an unsaturated ring;

or a pharmaceutically acceptable salts thereof.

2. **(Currently Amended)** ~~Use~~ The method according to claim 1, wherein A is -O- and B is -CHR³-, or A is -O- and B is -S-.

3. **(Currently Amended)** ~~Use~~ The method according to claim 1, wherein R² and R³ form a chemical bond.

4. **(Currently Amended)** ~~Use~~ The method according to claim 1, wherein R³ is OH, NH₂ or F.


5. **(Currently Amended)** ~~Use~~ The method according to claim 1, wherein R¹ is H.

6. **(Currently Amended)** ~~Use~~ The method according to claim 1, wherein C₀-C₃-alkylene-D-C₀-C₃-alkylene is oxymethylene, oxyethylene or oxypropylene.

7. **(Currently Amended)** ~~Use~~ The method according to claim 1, wherein C₀-C₃-alkylene-D-C₀-C₃-alkylene is aminomethylene, aminoethylene or aminopropylene.

8. **(Currently Amended)** ~~Use~~ The method according to claim 1, wherein at least two of R⁶, R⁷ and R⁸ have an aromatic nature.

9. **(Currently Amended)** ~~Use~~ The method according to claim 1, wherein R⁶ is optionally substituted phenyl.
10. **(Currently Amended)** ~~Use~~ The method according to claim 9, wherein R⁸ is optionally substituted phenyl or pyridyl.
11. **(Currently Amended)** ~~Use~~ The method according to claim 1, wherein E is C.
12. **(Original)** A compound of the formula I



where

A is O, S or CH₂;

B is O, S or CHR³;

R¹ is H, C₁-C₅ alkyl, C₂-C₅ alkenyl, C₂-C₅ alkynyl or a 5 or 6 membered, saturated or unsaturated ring containing 0 to 3 heteroatoms selected from N, O and S, the alkyl, alkenyl, alkynyl or ring being independently optionally substituted with R⁴;

R² is H, F;

R³ is H, F, OH, NH₂ or a pharmaceutically acceptable ester, amide or ether thereof; or

R² and R³ together form a chemical bond;

D is ONHCO-, -CONH-, -O-, -C(=O)-, -CH=CH-, -C≡C-, -NR⁵-;

R⁴ is independently selected from hydrogen, halo, cyano, amino, nitro, carboxy, carbamoyl, hydroxy, oxo, C₁-C₅ alkyl, C₁-C₅ haloalkyl, C₁-C₅ alkyloxy, C₁-C₅ alkanoyl, C₁-C₅ alkanoyloxy,

C₁-C₅ alkylthio, -N(C₀-C₃-alkyl)₂, hydroxymethyl, aminomethyl, carboxymethyl; -SO_nN(C₀-C₃-alkyl), -SO_nC₁-C₅-alkyl, where n is 1 or 2;

R⁵ is H, C₁-C₄-alkyl, C₁-C₄-alkanoyl;

E is Si or C;

R⁶ and R⁷ are independently a stable monocyclic, bicyclic or tricyclic ring system which has an aromatic nature and wherein each ring has 0 to 3 heteroatoms selected from N, O and S;

R⁸ is C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, or a stable monocyclic, bicyclic or tricyclic ring system which is saturated or unsaturated and in which each ring has 0 to 3 heteroatoms selected from N, O and S;

R⁶, R⁷ and R⁸ are independently optionally substituted with R⁴;

with the proviso that if the group C₀-C₃alkyl-D-C₀-C₃ alkyl is -O-CH₂-, then the group

E(R⁶)(R⁷)(R⁸) is not CPh₃ (trityl), methoxylated trityl or tert.butyldiphenylsilyl;

and pharmaceutically acceptable salts thereof.

13. **(Original)** A compound according to claim 12, wherein A is -O- and B is -CHR³-, or A is -O and B is -S-.

14. **(Original)** A compound according to claim 12, wherein R² and R³ form a chemical bond.

15. **(Original)** A compound according to claim 12, wherein R³ is OH, NH₂ or F.

16. **(Original)** A compound according to claim 12, wherein R¹ is H.

17. **(Original)** A compound according to claim 12, wherein C₀-C₃-alkylene-D-C₀-C₃-alkylene is oxymethylene, oxyethylene or oxypropylene.

18. **(Original)** A compound according to claim 12, wherein C₀-C₃-alkylene-D-C₀-C₃-alkylene is aminomethylene, aminoethylene or aminopropylene.

19. **(Original)** A compound according to claim 12, wherein R⁶ is optionally substituted phenyl.

20. **(Original)** A compound according to claim 19 wherein R⁷ is optionally substituted phenyl or pyridyl.
21. **(Original)** A compound according to claim 12 wherein E is C.
22. **(Currently Amended)** A pharmaceutical composition comprising a compound as defined in ~~any of claims 12-21~~ and a pharmaceutically acceptable carrier or diluent therefor.
23. **Canceled**
24. **Canceled.**